SCG presents solutions aimed at enhancing business value and reducing costs for hotel groups, banquet halls, office buildings, hospitals, educational institutions, and industrial factories. These solutions cover various business needs, ensuring
Emma Ciafaloni, MD, FAAN, explores the groundbreaking approval of onasemnogene abeparvovec-xioi for spinal muscular atrophy and its impact on the treatment paradigm for this rare disease.
Ryan Haumschild, PharmD, MS, MBA, and Mary Pak, MD, FACP, consider FDA-approved gene therapies for hemophilia, spinal muscular atrophy, and Duchenne muscular dystrophy, exploring their genetic foundations, the FDA approval process, and considerations for therapeutic value and cost.
Intensive surveillance after resection on patients with colorectal cancer (CRC) was less cost-effective in stage I but most cost-effective in stage II and III disease.
Emma Ciafaloni, MD, FAAN, describes the key differences among viral vectors used in gene therapy, highlighting their applications and strengths in targeting specific diseases.